Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Replicel Life Sciences Inc (TSV: RP )

0.0100 UNCHANGED
Streaming Delayed Price Updated: 1:37 PM EST, Nov 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.0100
Bid (Size) 0.0100 (4,950)
Ask (Size) 0.0150 (290)
Prev. Close 0.0100
Today's Range 0.0100 - 0.0100
52wk Range 0.0100 - 0.1000
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
RealPage Announces Strategic Partnership with Habitat for Humanity International to Build Housing in Local Communities
From RealPage, Inc.
Via Business Wire
RealPage Accelerates the Pace of Innovation for Multifamily with Market-Leading AI-Enabled Front Office Suite
From RealPage, Inc.
Via Business Wire

Performance

YTD
-83.33%
-83.33%
1 Month
-80.00%
-80.00%
3 Month
-80.00%
-80.00%
6 Month
-80.00%
-80.00%
1 Year
-83.33%
-83.33%

More News

Read More
RealPage Unveils New Multifamily Rental Trends
From RealPage
Via Business Wire
RepliCel Provides Corporate Update
Via ACCESSWIRE
RepliCel Announces Material Patent Milestones in Key Markets
Via ACCESSWIRE
RealPage Awarded 2023 ENERGY STAR Partner of the Year for Sustained Excellence
From RealPage
Via Business Wire
Key Cannabis Exec Changes You Need To Know About: Curaleaf Names Director Of Social Equity & More Industry Appointments
Via Benzinga
Grabbing Opportunity In Texas Migration Numbers, Rental Fund Buys Dallas-Area Single-Family Home Development
Via Benzinga
DermaPrecise(TM) Injection System Shown to Produce Consistently High Cell Count and Viability for Cell Therapy Injections
Via ACCESSWIRE
RepliCel’s Manufacturing Inspected by Japan’s PMDA
From RepliCel Life Sciences, Inc.
Via AccessWire
RepliCel’s Manufacturing Inspected by Japan’s PMDA
Via ACCESSWIRE
CORRECTION: Independent Laboratory Test Results Confirm Value of DermaPreciseTM Injection Consistency in Clinical Simulation Testing
Via ACCESSWIRE
CORRECTION: Independent Laboratory Test Results Confirm Value of DermaPreciseTM Injection Consistency in Clinical Simulation Testing
From RepliCel Life Sciences, Inc.
Via AccessWire
Independent Laboratory Test Results Confirm Value of DermaPrecise (TM) Injection Consistency in Clinical Simulation Testing
Via ACCESSWIRE
Independent Laboratory Test Results Confirm Value of DermaPrecise (TM) Injection Consistency in Clinical Simulation Testing
From RepliCel Life Sciences, Inc.
Via AccessWire
RepliCel Announces Material Patent Milestones
From RepliCel Life Sciences, Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
RepliCel Closed Final Tranche of Strategic Investment Commitment
From RepliCel Life Sciences, Inc.
Via AccessWire
RepliCel Terminates License Agreement with Shiseido
From RepliCel Life Sciences, Inc.
Via AccessWire
RealPage Agrees to Acquire HomeWiseDocs, The Premier Provider of Disclosure Management Services to the Community Association Industry
From RealPage, Inc.
Via Business Wire
RepliCel Ships DermaPrecise(TM) Injector Prototypes and Consumables to Independent Laboratory for Clinical Simulation Testing
From RepliCel Life Sciences, Inc.
Via AccessWire
RepliCel’s Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to its Japanese Regulatory and Clinical Study Management Team
From RepliCel Life Sciences, Inc.
Via AccessWire
RepliCel Announces DermaPrecise Trademark for Dermal Injector Product Line
From RepliCel Life Sciences, Inc.
Via AccessWire
RepliCel Announces Dermal Injector Update
From RepliCel Life Sciences, Inc.
Via AccessWire
RepliCel Files Notice of Arbitration against Shiseido Company to Resolve its License Agreement Dispute Regarding its Androgenetic Alopecia Cell Therapy
From RepliCel Life Sciences, Inc.
Via AccessWire
RepliCel Life Sciences Appoints One of Japan's Foremost Regenerative Medicine Industry Business Leaders as Strategic Advisor
From RepliCel Life Sciences, Inc.
Via AccessWire
Topics Economy
Exposures Economy
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.